☆ 4.8 Review

Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.
Article Immunology

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy

Shahryar Khoshtinat Nikkhoi et al.

Summary: The objective of this study was to develop a bispecific killer cell engager (BiKE) with high affinity and selectivity for CD16a receptor to improve NK cell-based cancer immunotherapy. High affinity anti-CD16a and anti-HER2 VHH clones were isolated using phage display and fused to create BiKE:HER2/CD16a. The results showed that BiKE:HER2/CD16a can activate NK cells to release cytokines and kill HER2(+) cancer cells more effectively than existing monoclonal antibodies.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Article Cell Biology

Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3

Antonio Arulanandam et al.

Summary: GPC3 is highly expressed in multiple solid tumors and is barely expressed in adult normal tissues except the placenta. NKp46 activation receptor is expressed in all-natural killer cells, including tumor-infiltrating NK cells. CYT-303 is a multifunctional antibody that targets both GPC3 and NKp46 to mediate NK cell-redirected killing of HCC tumors.

CELLS (2023)

Add to Collection
Article Oncology

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Satoko Kakiuchi-Kiyota et al.

Summary: Despite the current incurability of multiple myeloma (MM), the novel treatment, RO7297089, shows potential as an effective and well-tolerated therapy. By targeting BCMA and CD16A, RO7297089 induces lysis of MM cells and has a favorable safety profile, as evidenced by in vitro cytokine release and animal studies.

LEUKEMIA (2022)

Add to Collection
Article Oncology

Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia

Natalia Colomar-Carando et al.

Summary: NK cells have promising potential in antitumor immunotherapy, especially in the treatment of hematologic malignancies. By targeting specific molecules on tumor cells, NK cell activity can be boosted to effectively kill tumor cells. NK cell engagers targeting CD19 have shown good efficacy.

CANCER IMMUNOLOGY RESEARCH (2022)

Add to Collection
Article Multidisciplinary Sciences

Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv

Merve Arslan et al.

Summary: Single chain antibody fragments (scFvs) are widely used in diagnostics and therapeutics due to their small size and various engineering approaches. The design of the linker between the variable heavy and light chains of scFv plays a crucial role in its construction. The flexibility of the linker is determined by its length and sequence content, and flexible linkers such as glycine-serine (GS) are commonly preferred. However, repeated sequences in GS linkers can cause problems in PCR-based engineering and immunogenicity.

SCIENTIFIC REPORTS (2022)

Add to Collection
Article Oncology

Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells

Wen Jiang et al.

Summary: Blocking the Tim-3 pathway enhances the anti-tumor activity of NK cells against multiple myeloma, both in vitro and in vivo.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Review Oncology

CAR-NK cells for cancer immunotherapy: from bench to bedside

Leisheng Zhang et al.

Summary: This article mainly focuses on the latest updates, opportunities, and challenges of CAR-NK cell-based tactics in cancer immunotherapy. CAR-NK cells have the potential to improve efficacy and control adverse effects, while also meeting the demand for large-scale manufacture.

BIOMARKER RESEARCH (2022)

Add to Collection
Review Oncology

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok et al.

Summary: This review summarizes the clinical status of allogeneic NK cell-based therapies for hematological and solid tumors, discusses different cell sources, engineering methods, and combination therapies. It also reviews regulatory challenges and the competitive landscape, providing a comprehensive overview.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Review Immunology

Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

Feifei Li et al.

Summary: This review provides an overview of the role of natural killer (NK) cells and antibody-dependent cellular cytotoxicity (ADCC) in targeted therapy of HER2-positive breast cancer, as well as recent strategies to leverage our knowledge of NK cells and ADCC as an immunotherapy approach.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Oncology

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Stephanie Sasse et al.

Summary: The efficacy of bispecific antibody AFM13 in patients with relapsed classical Hodgkin lymphoma is modest, with an objective response rate of 16.7% and a 12-month progression-free survival rate of 12.6% in all evaluated patients.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection
Review Oncology

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course

Mengjie Jiang et al.

Summary: ICIs are a revolutionary breakthrough in cancer treatment by modulating the patient's own immune system. The clinical application of ICIs is still in its early stages and requires continuous adjustment of the dosing regimens. Many clinical data have shown significant anticancer effects of ICIs at lower doses, indicating the need for reevaluation and optimization of the dosing regimens.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Pharmacology & Pharmacy

Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma

Hao Cai et al.

Summary: This study characterized the nonclinical PK, PD, sBCMA, and sCD16 changes following administration of RO7297089, developed a TMDD model, and used simulations to inform clinical dose regimens.

AAPS JOURNAL (2022)

Add to Collection
Review Biochemistry & Molecular Biology

The journey of CAR-T therapy in hematological malignancies

Junru Lu et al.

Summary: Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, but some patients may experience relapse, leading to the need for novel strategies to overcome resistance and relapse mechanisms. Significant technological advancements have been made, and the clinical application of CAR-T cell therapy is constantly being explored and improved.

MOLECULAR CANCER (2022)

Add to Collection
Review Immunology

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers

Sheena Pinto et al.

Summary: Bi-, tri- and multispecific antibodies have revolutionized targeted cancer immunotherapies, allowing immune effector cells to selectively eliminate malignant cells. However, there are still major challenges to overcome, such as enhancing efficacy in solid tumors and minimizing toxicities and immunogenicity.

TRENDS IN IMMUNOLOGY (2022)

Add to Collection
Review Oncology

Current Progress of CAR-NK Therapy in Cancer Treatment

Zhaojun Pang et al.

Summary: CAR-NK therapy, as a promising cancer treatment, attracts attention due to its lack of adverse effects observed in CAR-T therapies and its effectiveness in killing cancer cells. However, CAR-NK therapy faces challenges such as difficulties in transduction and expansion of NK cells, as well as time, cost, and potential biohazard issues.

CANCERS (2022)

Add to Collection
Meeting Abstract Hematology

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Kim Anh Giang et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

Liang Lin et al.

BLOOD (2022)

Add to Collection
Article Oncology

Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study

Mojgan Astaneh et al.

Summary: Pre-treatment of NK cells with anti-PD-1 and anti-Tim-3 blocking antibodies cannot improve their functional properties in CLL patients.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2022)

Add to Collection
Article Immunology

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity

Matthew D. Blunt et al.

Summary: This study demonstrates that KIR2DS2 marks a population of NK cells primed for anticancer activity and is associated with enhanced NK cell-mediated cytotoxicity.

JOURNAL OF IMMUNOLOGY (2022)

Add to Collection
Review Oncology

Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J. Laskowski et al.

Summary: This review provides an overview of NK cell-based immunotherapies, discussing strategies to increase NK cell cytotoxicity and persistence and highlighting the current challenges and future opportunities for the design of next-generation NK cell therapies.

NATURE REVIEWS CANCER (2022)

Add to Collection
Article Immunology

Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers

Uwe Reusch et al.

Summary: Innate cell engager (ICE(R)) constructs are bispecific tetravalent antibodies that target tumor antigens and engage natural killer (NK) cell and macrophage receptors simultaneously. This study investigates the binding affinity, antitumor activity, and cryopreservation feasibility of ICE (R) constructs targeting EpCAM and NK cell receptors CD16A, NKG2D, or NKp46. The results indicate that high-affinity NK cell and EpCAM/CD16A ICE (R) complexes have superior NK-cell-mediated elimination of EpCAM-expressing tumor cells. Additionally, the potency and efficacy of these complexes remain unaffected after freezing and thawing.

ANTIBODIES (2022)

Add to Collection
Review Immunology

Review Article Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody

Dain Moon et al.

Summary: In the era of immunotherapeutic control of cancers, advances in biotechnology, especially in Ab engineering, have provided new candidates for therapeutic immunooncology. Among them, TCEBs that target both T cells and tumor cells through tumor cell specific antigens are the most promising BsAbs. The development of TCEBs and their diverse formats, characteristics, and functional mechanisms are discussed, including the challenges and drawbacks associated with current TCEB therapy.

IMMUNE NETWORK (2022)

Add to Collection
Review Biochemistry & Molecular Biology

NK cells and ILCs in tumor immunotherapy

Simona Sivori et al.

Summary: Innate immune cells, especially NK cells, play an important role in tumor immunotherapy by controlling tumor growth and metastasis. Various approaches have been developed, such as using IL-15 to improve NK cell function and utilizing NK cell engagers to activate NK cells. Additionally, NK cells may express inhibitory checkpoints like PD-1, which can be targeted for therapeutic use against certain tumors.

MOLECULAR ASPECTS OF MEDICINE (2021)

Add to Collection
Article Oncology

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

Upasana Sunil Arvindam et al.

Summary: The development of a CLEC12A TriKE molecule targeting AML blasts and LSCs, which activates NK cells and drives NK cell priming while sparing healthy cells, highlights the potential clinical efficacy for the treatment of AML.

LEUKEMIA (2021)

Add to Collection
Meeting Abstract Hematology

Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies

Irene Raitman et al.

BLOOD (2021)

Add to Collection
Article Immunology

Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement

Lukas Pekar et al.

Summary: Novel immunoligands targeting activating NK cell receptors were generated and showed enhanced killing of tumor cells by NK cells. Incorporating affinity-matured ligands for NK cell-activating receptors may represent an effective strategy for potent cancer immunotherapy agents.

JOURNAL OF IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response

Adeline Raynaud et al.

Summary: The NKG2D receptor, expressed by cytotoxic immune cells, plays a central role in immune responses against cellular threats. Specific antibodies targeting NKG2D can modulate immune responses and show both activating and inhibitory effects. Bispecific antibodies targeting NKG2D and other molecules such as HER2 on tumor cells can induce cytotoxicity in a tumor-specific manner. These antibodies can retain cytotoxic activity in the presence of ligands, overcoming immunosuppressive effects in the microenvironment.

ONCOIMMUNOLOGY (2021)

Add to Collection
Article Oncology

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Lucila N. Kerbauy et al.

Summary: The study suggests that using bispecific engagers and cytokine pre-activation can enhance NK-cell cytotoxicity against NK-resistant cancers. Additionally, there are differences in treatment response based on the source of NK cells.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Review Immunology

CAR-NK Cells: From Natural Basis to Design for Kill

Muhammad Babar Khawar et al.

Summary: CAR-engineered T lymphocytes have shown success in treating blood cancers but face limitations such as potential fatal toxicity and high costs. On the other hand, NK cells are the focus of immunological research as promising immunotherapeutic candidates due to their unique recognition mechanisms and powerful cytotoxic effects.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor

Elisa C. Toffoli et al.

Summary: A novel bispecific single domain antibody (VHH) targeting CD16 on NK cells and EGFR on tumor cells enhanced NK cell activation and cytotoxicity, showing potential for cancer therapy. This approach demonstrated efficacy in controlling tumor growth in colorectal cancer cell co-cultures, suggesting promise for further exploration in NK cell-based therapeutic approaches.

CANCERS (2021)

Add to Collection
Review Biotechnology & Applied Microbiology

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors

Evan Tan et al.

Summary: Animal cell-based expression platforms are capable of producing complex biomolecules, with human cell lines offering the advantage of more human-like post-translational modifications. HEK293 is widely utilized due to its high transfectivity, rapid growth rate, and ability to grow in a serum-free, suspension culture. This review discusses the use of HEK293 cells in biotherapeutics production, comparing their usage against other host cell lines and summarizing factors influencing the choice of host cell lines.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)

Add to Collection
Review Oncology

A comprehensive comparison between camelid nanobodies and single chain variable fragments

Yasaman Asaadi et al.

Summary: By comparing the structure and properties of camelid antibodies (VHHs) and single-chain variable fragments (scFvs), it can be determined which one is more suitable for their respective therapeutic, diagnostic, and research applications.

BIOMARKER RESEARCH (2021)

Add to Collection
Article Immunology

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2+1 Common Light Chain Antibody Architecture

Jan P. Bogen et al.

Summary: In this study, chicken-derived antibodies targeting EGFR were affinity matured and used to isolate CD16a- and PD-L1-specific monoclonal antibodies. Humanized bispecific and trispecific variants were generated, showing elevated ADCC and synergistic effects of trispecific antigen binding. This work paves the way for the engineering of tri- and oligospecific therapeutic antibodies derived from avian immunizations.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas

Claudia Manuela Arnone et al.

Summary: In this study, a combination of oncolytic adenoviruses and a gene therapy approach using a bispecific T-cell engager was developed and found to significantly enhance the antitumor efficacy in pediatric high-grade gliomas. The strategy showed promising results in vitro and in vivo models, supporting its potential for clinical translation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Nanoscience & Nanotechnology

Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications

Ah-Young Song et al.

Summary: The study introduces bispecific antibodies (NKABs) targeting NKG2D and 2B4 receptors for assessing NK cell functions, which can trigger selective cytotoxicity and IFN-gamma production in NK cells. These antibodies provide an effective and reliable method for measuring NK cell function in diverse diseases.

ACS APPLIED MATERIALS & INTERFACES (2021)

Add to Collection
Article Biotechnology & Applied Microbiology

Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+NK cells to target myeloid leukemia

Emily Chiu et al.

Summary: The researchers developed an immune therapy called NKG2C-KE, which directs specific types of NK cells to attack leukemia cells. This method showed promising results in experiments and could potentially become a new treatment strategy for leukemia.

MOLECULAR THERAPY (2021)

Add to Collection
Article Oncology

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

Daniel A. Vallera et al.

Summary: HER2 is a crucial marker in breast cancer therapy, but targeting it in ovarian cancer has shown disappointing results, requiring a more comprehensive approach. A new tri-specific biological drug has been designed to enhance NK cell killing of cancer cells and suppress tumor growth by delivering a natural cytokine signal. The study focuses on a nanobody platform technology that combines targeting and cytokine priming to improve efficacy in ovarian cancer treatment.

CANCERS (2021)

Add to Collection
Review Cell Biology

Affecting HEK293 Cell Growth and Production Performance by Modifying the Expression of Specific Genes

Laura Abaandou et al.

Summary: The HEK293 cell line is favored for producing biotherapeutics due to its human origin, despite its inferior growth and production properties compared to non-human cell lines. Through genetic modifications and optimization, the performance of the HEK293 cell line has been greatly enhanced.

CELLS (2021)

Add to Collection
Review Oncology

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

Hui Lu et al.

Summary: The approval of CD19 CAR-engineered T cell products in B-cell malignancies is a breakthrough in CAR-T cell immunotherapy. However, limitations such as GVHD and other adverse effects restrict their wider applications. CAR-NK cells, with their unique characteristics, are considered promising candidates for cellular immunotherapy, offering potential off-the-shelf products for immediate clinical use without HLA-matching restrictions. Researchers are shifting focus from CAR-T cells to CAR-NK cells, discussing their advantages and challenges in clinical applications.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Review Medicine, Research & Experimental

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

Marlena Surowka et al.

Summary: CrossMab technology, introduced in 2011, enables correct light-chain and heavy-chain association in bispecific antibodies and has become one of the most mature and widely applied technologies in the field. Multiple bispecific antibodies based on CrossMab technology have entered clinical trials, demonstrating potential therapeutic value in different disease settings.

MABS (2021)

Add to Collection
Article Medicine, Research & Experimental

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Susanne Wingert et al.

Summary: The newly developed bispecific antibody AFM24 shows high efficacy against tumor cells expressing varying levels of EGFR, without causing significant toxicity. This antibody demonstrates potent cell killing effects both in vitro and in vivo, indicating its potential as a promising cancer therapy.

MABS (2021)

Add to Collection
Review Genetics & Heredity

Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use

Matthew D. Blunt et al.

INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2020)

Add to Collection
Review Oncology

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

Nina Shah et al.

LEUKEMIA (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren et al.

MOLECULAR CANCER (2020)

Add to Collection
Article Multidisciplinary Sciences

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

Lionel Rouge et al.

SCIENCE (2020)

Add to Collection
Review Immunology

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

Heliang Li et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection
Article Oncology

BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma

Yang Wang et al.

JOURNAL OF IMMUNOTHERAPY (2020)

Add to Collection
Article Cell Biology

Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy

Loris Zamai et al.

CELLS (2020)

Add to Collection
Review Pharmacology & Pharmacy

NKp30-A prospective target for new cancer immunotherapy strategies

Pedro F. Pinheiro et al.

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

Kin Man Au et al.

SCIENCE ADVANCES (2020)

Add to Collection
Article Multidisciplinary Sciences

CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

Fangkun Liu et al.

SCIENTIFIC REPORTS (2020)

Add to Collection
Article Immunology

Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo

Yu Kato et al.

IMMUNITY (2020)

Add to Collection
Review Medicine, General & Internal

CAR-NK cells: A promising cellular immunotherapy for cancer

Guozhu Xie et al.

EBIOMEDICINE (2020)

Add to Collection
Article Oncology

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

Daniel A. Vallera et al.

CANCERS (2020)

Add to Collection
Review Oncology

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

Hilma J. van der Horst et al.

CANCERS (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Functional Domain Order of an Anti-EGFR x Anti-CD16 Bispecific Diabody Involving NK Cell Activation

Atsushi Kuwahara et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Article Oncology

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers

Ying Cheng et al.

CANCER BIOLOGY & MEDICINE (2020)

Add to Collection
Meeting Abstract Oncology

Targeting autopalmitoylation of TEAD transcription factors

Xu Wu

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)

Add to Collection
Article Medicine, Research & Experimental

Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats

Ami Miller et al.

MABS (2020)

Add to Collection
Review Immunology

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Simona Sivori et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

Add to Collection
Editorial Material Oncology

The NKG2A immune checkpoint - a new direction in cancer immunotherapy

Benjamin C. Creelan et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection
Editorial Material Economics

CAR T-cells: costs, comparisons, and commentary

Annette E. Hay et al.

JOURNAL OF MEDICAL ECONOMICS (2019)

Add to Collection
Review Cell Biology

Mechanisms of natural killer cell-mediated cellular cytotoxicity

Isabel Prager et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2019)

Add to Collection
Article Medicine, Research & Experimental

TNF--induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer

Yujia Zheng et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

Add to Collection
Article Biochemistry & Molecular Biology

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Laurent Gauthier et al.

CELL (2019)

Add to Collection
Article Immunology

NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing

Isabel Prager et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

Add to Collection
Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection
Review Immunology

The Natural Cytotoxicity Receptors in Health and Disease

Alexander David Barrow et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Article Oncology

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

Martine Bagot et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Oncology

PD-L1 expression levels on tumor cells affect their immunosuppressive activity

Yang Zheng et al.

ONCOLOGY LETTERS (2019)

Add to Collection
Meeting Abstract Hematology

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Jennifer Watkins-Yoon et al.

BLOOD (2019)

Add to Collection
Article Gastroenterology & Hepatology

Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma

Haoyu Sun et al.

HEPATOLOGY (2019)

Add to Collection
Review Chemistry, Medicinal

Immunogenicity of Protein Pharmaceuticals

Robert Dingman et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2019)

Add to Collection
Review Oncology

NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives

Cristiana Lo Nigro et al.

ANNALS OF TRANSLATIONAL MEDICINE (2019)

Add to Collection
Review Immunology

Design and Production of Bispecific Antibodies

Qiong Wang et al.

ANTIBODIES (2019)

Add to Collection
Article Hematology

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Martin Felices et al.

BLOOD ADVANCES (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Current Progress in CAR-T Cell Therapy for Solid Tumors

Shuo Ma et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)

Add to Collection
Article Oncology

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells

Yufeng Wang et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Review Pharmacology & Pharmacy

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

Ping-Pin Zheng et al.

DRUG DISCOVERY TODAY (2018)

Add to Collection
Article Cell Biology

Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells

Katja Srpan et al.

JOURNAL OF CELL BIOLOGY (2018)

Add to Collection
Article Medicine, Research & Experimental

The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

Natasha A. Pereira et al.

MABS (2018)

Add to Collection
Article Immunology

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Qing Zhang et al.

NATURE IMMUNOLOGY (2018)

Add to Collection
Article Hematology

Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma

Francesco Ceppi et al.

TRANSFUSION (2018)

Add to Collection
Review Chemistry, Medicinal

Bispecific antibodies: design, therapy, perspectives

Sergey E. Sedykh et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2018)

Add to Collection
Article Oncology

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Wing Keung Chan et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection
Review Immunology

NKG2D: A Master Regulator of Immune Cell Responsiveness

Felix M. Wensveen et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Immunology

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction

Nicholas J. W. Easom et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Immunology

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Hans H. Oberg et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Oncology

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity

Amelia Roman Aguilera et al.

ONCOIMMUNOLOGY (2018)

Add to Collection
Review Oncology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations

Judith A. Seidel et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Pascale Andre et al.

CELL (2018)

Add to Collection
Review Oncology

Universal CARs, universal T cells, and universal CAR T cells

Juanjuan Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Cell Biology

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

Dionysos Slaga et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection
Review Immunology

Engineering IgG-Like Bispecific AntibodiesAn Overview

Simon Krah et al.

ANTIBODIES (2018)

Add to Collection
Review Immunology

Natural killer cells and other innate lymphoid cells in cancer

Laura Chiossone et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Add to Collection
Meeting Abstract Hematology

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross et al.

BLOOD (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Targeting IL-2: an unexpected effect in treating immunological diseases

Congxiu Ye et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)

Add to Collection
Article Hematology

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Hyun Don Yun et al.

BLOOD ADVANCES (2018)

Add to Collection
Review Immunology

IgG Antibody 3D Structures and Dynamics

Jacob White Jay et al.

ANTIBODIES (2018)

Add to Collection
Review Immunology

The Broad Spectrum of Human Natural Killer Cell Diversity

Aharon G. Freud et al.

IMMUNITY (2017)

Add to Collection
Review Immunology

Tim-3 and its role in regulating anti-tumor immunity

Madhumita Das et al.

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection
Article Biochemistry & Molecular Biology

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells

Thorsten Gantke et al.

PROTEIN ENGINEERING DESIGN & SELECTION (2017)

Add to Collection
Article Oncology

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

Jorg U. Schmohl et al.

CANCER RESEARCH AND TREATMENT (2017)

Add to Collection
Meeting Abstract Oncology

AFM26-A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

Thorsten Gantke et al.

CANCER RESEARCH (2017)

Add to Collection
Review Biochemistry & Molecular Biology

Affibody molecules as engineered protein drugs

Fredrik Y. Frejd et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2017)

Add to Collection
Article Oncology

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+Colorectal Cancer Cells

J. U. Schmohl et al.

TARGETED ONCOLOGY (2016)

Add to Collection
Article Biochemistry & Molecular Biology

B7H6-derived Peptides Trigger TNF-α-dependent Immunostimulatory Activity of Lymphocytic NK92-MI Cells

Mariana Phillips et al.

BIOPOLYMERS (2016)

Add to Collection
Meeting Abstract Oncology

Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII plus tumors

Kristina Ellwanger et al.

CANCER RESEARCH (2016)

Add to Collection
Article Oncology

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Dhifaf Sarhan et al.

CANCER RESEARCH (2016)

Add to Collection
Article Oncology

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Daniel A. Vallera et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Article Immunology

Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets

Aura Muntasell et al.

JOURNAL OF IMMUNOLOGY (2016)

Add to Collection
Article Cell Biology

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Rizwan Romee et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Add to Collection
Article Multidisciplinary Sciences

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

Reza Ghasemi et al.

NATURE COMMUNICATIONS (2016)

Add to Collection
Article Oncology

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Stephen J. Blake et al.

CANCER DISCOVERY (2016)

Add to Collection
Article Oncology

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

Joerg U. Schmohl et al.

ONCOTARGET (2016)

Add to Collection
Article Education, Scientific Disciplines

Can we make a better match or mismatch with KIR genotyping?

Rohtesh S. Mehta et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)

Add to Collection
Article Immunology

NKG2C+CD57+ Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8+ T Cell Evolution towards Senescence

John Heath et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2016)

Add to Collection
Article Immunology

Phenotypic and Functional Dysregulated Blood NK cells in colorectal cancer Patients can Be activated by cetuximab Plus IL-2 or IL-15

Yamila Sol Rocca et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection
Article Immunology

Features of Memory-Like and PD-1+ Human nK Cell Subsets

Mariella Della Chiesa et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection
Review Oncology

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Xiuyan Wang et al.

MOLECULAR THERAPY-ONCOLYTICS (2016)

Add to Collection
Review Oncology

NK cells and cancer: you can teach innate cells new tricks

Maelig G. Morvan et al.

NATURE REVIEWS CANCER (2016)

Add to Collection
Meeting Abstract Hematology

Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma

Thorsten Gantke et al.

BLOOD (2016)

Add to Collection
Meeting Abstract Hematology

CD20 Tcb (RG6026), a Novel 2:1 T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac et al.

BLOOD (2016)

Add to Collection
Article Hematology

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe et al.

BLOOD (2015)

Add to Collection
Article Biochemistry & Molecular Biology

Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia

Gang Deng et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Add to Collection
Article Oncology

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

Kevin C. Conlon et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection
Article Immunology

CD160 is essential for NK-mediated IFN-γ production

Tony C. Tu et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2015)

Add to Collection
Article Immunology

DNAM-1 controls NK cell activation via an ITT-like motif

Zhanguang Zhang et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2015)

Add to Collection
Article Oncology

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Jingjing Wu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection
Review Biochemistry & Molecular Biology

Alternative molecular formats and therapeutic applications for bispecific antibodies

Christoph Spiess et al.

MOLECULAR IMMUNOLOGY (2015)

Add to Collection
Article Oncology

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity

Matthias Peipp et al.

ONCOTARGET (2015)

Add to Collection
Article Immunology

Polyclonal expansion of NKG2C+ NK cells in TAP-deficient patients

Vivien Beziat et al.

FRONTIERS IN IMMUNOLOGY (2015)

Add to Collection
Article Oncology

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape

Silvia Pesce et al.

ONCOIMMUNOLOGY (2015)

Add to Collection
Article Oncology

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

Gregory L. Beatty et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection
Review Biochemistry & Molecular Biology

Engineering disulfide bonds within an antibody

Yoshihisa Hagihara et al.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)

Add to Collection
Article Hematology

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Michelle K. Gleason et al.

BLOOD (2014)

Add to Collection
Letter Oncology

Efficient generation of human natural killer cell lines by viral transformation

B. Vogel et al.

LEUKEMIA (2014)

Add to Collection
Article Medicine, Research & Experimental

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

Uwe Reusch et al.

MABS (2014)

Add to Collection
Article Multidisciplinary Sciences

The immune synapse clears and excludes molecules above a size threshold

Adam N. R. Cartwright et al.

NATURE COMMUNICATIONS (2014)

Add to Collection
Review Immunology

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition

Eric O. Long et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)

Add to Collection
Article Hematology

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)

Rizwan Romee et al.

BLOOD (2013)

Add to Collection
Article Oncology

Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells

Daniel A. Vallera et al.

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)

Add to Collection
Article Oncology

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Andres Wiernik et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection
Review Immunology

Dynamics of NK cell interactions in vivo

Jacques Deguine et al.

IMMUNOLOGICAL REVIEWS (2013)

Add to Collection
Article Immunology

Membrane-Type 6 Matrix Metalloproteinase Regulates the Activation-Induced Downmodulation of CD16 in Human Primary NK Cells

Giovanna Peruzzi et al.

JOURNAL OF IMMUNOLOGY (2013)

Add to Collection
Article Biotechnology & Applied Microbiology

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

Christoph Spiess et al.

NATURE BIOTECHNOLOGY (2013)

Add to Collection
Article Immunology

Matching cellular dimensions with molecular sizes

Michael Reth

NATURE IMMUNOLOGY (2013)

Add to Collection
Review Biochemistry & Molecular Biology

Strategies for the Production of Recombinant Protein in Escherichia coli

Gopal Jee Gopal et al.

PROTEIN JOURNAL (2013)

Add to Collection
Article Hematology

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger et al.

BLOOD (2012)

Add to Collection
Article Immunology

The effect of antigen size on the immunogenicity of antigen presenting cell targeted DNA vaccine

Rong Jia et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2012)

Add to Collection
Article Oncology

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Michelle K. Gleason et al.

MOLECULAR CANCER THERAPEUTICS (2012)

Add to Collection
Review Immunology

Molecular mechanisms of Treg-mediated T cell suppression

Angelika Schmidt et al.

FRONTIERS IN IMMUNOLOGY (2012)

Add to Collection
Review Immunology

Evolving role of 2B4/CD244 in T and NK cell responses during virus infection

Stephen N. Waggoner et al.

FRONTIERS IN IMMUNOLOGY (2012)

Add to Collection
Meeting Abstract Hematology

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 x CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Andres Wiernik et al.

BLOOD (2012)

Add to Collection
Article Oncology

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

Sophia Platonova et al.

CANCER RESEARCH (2011)

Add to Collection
Review Biochemical Research Methods

Strategies for extended serum half-life of protein therapeutics

Roland E. Kontermann

CURRENT OPINION IN BIOTECHNOLOGY (2011)

Add to Collection
Review Immunology

CD160: A unique activating NK cell receptor

Philippe Le Bouteiller et al.

IMMUNOLOGY LETTERS (2011)

Add to Collection
Article Medicine, Research & Experimental

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

Emilie Mamessier et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

Add to Collection
Article Immunology

Cutting Edge: NKp80 Uses an Atypical Hemi-ITAM To Trigger NK Cytotoxicity

Kevin M. Dennehy et al.

JOURNAL OF IMMUNOLOGY (2011)

Add to Collection
Article Biochemistry & Molecular Biology

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules

Nina Kronqvist et al.

PROTEIN ENGINEERING DESIGN & SELECTION (2011)

Add to Collection
Article Biochemistry & Molecular Biology

Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG

Kannan Gunasekaran et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Add to Collection
Article Gastroenterology & Hepatology

T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B

Ying Ju et al.

JOURNAL OF HEPATOLOGY (2010)

Add to Collection
Article Biochemistry & Molecular Biology

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

Jonathan H. Davis et al.

PROTEIN ENGINEERING DESIGN & SELECTION (2010)

Add to Collection
Review Immunology

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Martin F. Bachmann et al.

NATURE REVIEWS IMMUNOLOGY (2010)

Add to Collection
Review Oncology

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

Roland E. Kontermann

BIODRUGS (2009)

Add to Collection
Article Chemistry, Analytical

Engineering peptide linkers for scFv immunosensors

Zhihong Shen et al.

ANALYTICAL CHEMISTRY (2008)

Add to Collection
Review Oncology

The impact of PEGylation on biological therapies

Francesco M. Veronese et al.

BIODRUGS (2008)

Add to Collection
Article Oncology

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer

Antonino Musolino et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection
Article Oncology

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

Bernard M. Tijink et al.

MOLECULAR CANCER THERAPEUTICS (2008)

Add to Collection
Editorial Material Medicine, General & Internal

Targeting EGFR in colorectal cancer

Wells A. Messersmith et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection
Review Immunology

Formation and function of the lytic NK-cell immunological synapse

Jordan S. Orange

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection
Article Biochemistry & Molecular Biology

Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin

Dafne Mueller et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2007)

Add to Collection
Article Biochemistry & Molecular Biology

The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies

Veronica Quintero-Hernandez et al.

MOLECULAR IMMUNOLOGY (2007)

Add to Collection
Letter Oncology

CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases

B. Grzywacz et al.

LEUKEMIA (2007)

Add to Collection
Article Biotechnology & Applied Microbiology

Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides

Caroline Gronwall et al.

JOURNAL OF BIOTECHNOLOGY (2007)

Add to Collection
Article Hematology

Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction

Cyril Fauriat et al.

BLOOD (2007)

Add to Collection
Review Immunology

FcRn: the neonatal Fc receptor comes of age

Derry C. Roopenian et al.

NATURE REVIEWS IMMUNOLOGY (2007)

Add to Collection
Article Immunology

Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction

Stefan Welte et al.

NATURE IMMUNOLOGY (2006)

Add to Collection
Article Oncology

Tumor Imaging using a picomolar affinity HER2 binding affibody molecule

A Orlova et al.

CANCER RESEARCH (2006)

Add to Collection
Article Hematology

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

EP von Strandmann et al.

BLOOD (2006)

Add to Collection
Article Oncology

Soluble MICA in malignant diseases

S Holdenrieder et al.

INTERNATIONAL JOURNAL OF CANCER (2006)

Add to Collection
Article Hematology

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

YT Bryceson et al.

BLOOD (2006)

Add to Collection
Review Biotechnology & Applied Microbiology

Engineering novel binding proteins from nonimmunoglobulin domains

HK Binz et al.

NATURE BIOTECHNOLOGY (2005)

Add to Collection
Article Hematology

Arf6:: a new player in FcγRIIIA lymphocyte-mediated cytotoxicity

R Galandrini et al.

BLOOD (2005)

Add to Collection
Article Multidisciplinary Sciences

The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure

D Garrity et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Add to Collection
Article Biochemical Research Methods

Immunogenicity of engineered antibodies

WYK Hwang et al.

METHODS (2005)

Add to Collection
Article Hematology

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

D Pende et al.

BLOOD (2005)

Add to Collection
Article Cell Biology

Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcεRIγ and CD3ζ

IH Westgaard et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2004)

Add to Collection
Article Immunology

Cutting edge: Engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset

A Barakonyi et al.

JOURNAL OF IMMUNOLOGY (2004)

Add to Collection
Article Biochemistry & Molecular Biology

Molecular dissection of 2134 signaling: Implications for signal transduction by SLAM-related receptors

RY Chen et al.

MOLECULAR AND CELLULAR BIOLOGY (2004)

Add to Collection
Article Immunology

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma

ES Doubrovina et al.

JOURNAL OF IMMUNOLOGY (2003)

Add to Collection
Article Biochemistry & Molecular Biology

Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors

CE Foster et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Add to Collection
Article Immunology

NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway

DD Billadeau et al.

NATURE IMMUNOLOGY (2003)

Add to Collection
Article Immunology

The size of the synaptic cleft and distinct distributions of filamentous actin, ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses

FE McCann et al.

JOURNAL OF IMMUNOLOGY (2003)

Add to Collection
Article Oncology

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

WK Weng et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection
Article Multidisciplinary Sciences

Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity

P Le Bouteiller et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

Add to Collection
Article Immunology

The role of the NKG2D immunoreceptor in immune cell activation and natural killing

AM Jamieson et al.

IMMUNITY (2002)

Add to Collection
Article Multidisciplinary Sciences

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

L Ruggeri et al.

SCIENCE (2002)

Add to Collection
Article Hematology

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

G Cartron et al.

BLOOD (2002)

Add to Collection
Article Immunology

UL16-Binding proteins, novel MHC class I-Related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

CL Sutherland et al.

JOURNAL OF IMMUNOLOGY (2002)

Add to Collection
Article Immunology

X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells

S Parolini et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2000)

Add to Collection
Article Immunology

Crystal structure of the exctracellular domain of a human Fc gamma RIII

YH Zhang et al.

IMMUNITY (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.